Sandoz stock: October 28 results are due for Sandoz stock

Published on 10/16/2026 at 16:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays kept CHF 93.00 on October 12, 2026. Sandoz stock costs EUR 82.63 on October 16, 2026, up 1.62 percent on SIX.

Results and valuation ahead

Sandoz is scheduled to report third-quarter results on October 28, 2026.
Barclays maintained a CHF 93.00 target on October 12, 2026.
Sandoz stock costs EUR 82.63 at 4:12 p.m. CEST at Lang & Schwarz on October 16, 2026, up 1.62 percent on SIX versus CHF 75.26.
Sandoz trades at a P/E of 62.33 as of October 16, 2026.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz is scheduled to report its third-quarter results on October 28, 2026, according to Boursorama. Barclays maintained a CHF 93.00 price target on October 12, 2026, while Sandoz stock was valued at EUR 82.63 at Lang & Schwarz on October 16, 2026 at 4:12 p.m. CEST, up 1.62 percent on SIX versus CHF 75.26.

Analyst target stays above SIX price

According to Markets Insider, Barclays kept its Buy rating and CHF 93.00 target for Sandoz on October 12, 2026. Against the SIX price of CHF 76.48 on October 16, 2026, that target stood 21.60 percent higher.

The target gives the market a concrete valuation marker before the results date. The same report listed a consensus target of CHF 77.47, putting the Barclays target CHF 15.53 above that average.

Price position and trading range

Sandoz traded between a 52-week low of CHF 47.73 and a high of CHF 76.48 on the finance quote dated October 16, 2026. The current SIX price was therefore at the reported 52-week high, while the Lang & Schwarz euro quote stood at EUR 82.63.

Sandoz had a market capitalization of CHF 33.1 billion and volume of 514,289 shares as of October 16, 2026. Its average volume was 1,216,566 shares, so the session volume was below that average.

Valuation and reporting date

The stock carried a trailing P/E ratio of 62.33 and a dividend yield of 0.01 percent as of October 16, 2026. Those figures frame the October 28 reporting date, when investors can compare the third-quarter performance with the expectations cited by Jefferies.

In its September 23, 2026 report, Boursorama reported that Jefferies expected third-quarter constant-currency growth of 6.10 percent, with biosimilars growing 20.00 percent.

Comparison with peers

Sandoz: plus 1.62 percent, P/E 62.33, market capitalization CHF 33.1 billion

Teva (NYSE, USD): plus 0.56 percent, P/E 69.04, market capitalization USD 48.2 billion

Viatris (Nasdaq, USD): plus 0.49 percent, P/E minus 51.05, market capitalization USD 21.0 billion

What October 28 can clarify

The upcoming report can put the current valuation beside the latest operating trend. Jefferies had projected stronger biosimilar growth than generic-drug growth for the third quarter, making product mix an important comparison point.

The stock was trading at EUR 82.63 at Lang & Schwarz on October 16, 2026 at 4:12 p.m. CEST, up 1.62 percent on SIX versus CHF 75.26. The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.